Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04220931
Other study ID # P170913J
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date March 27, 2023
Est. completion date March 1, 2027

Study information

Verified date July 2023
Source Assistance Publique - Hôpitaux de Paris
Contact Frederic Prat, Prof
Phone 0033(1)40875663
Email frederic.prat@aphp.fr
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Surgery is required for the treatment of many pancreatic conditions, either malignant or benign. Mortality of pancreatic surgery can be up to 3% even in expert centers. Morbidity is high, postoperative pancreatic fistula (POPF) being the main postoperative complication. In its current definition (drain output of any measurable fluid >= postoperative day 3 with amylase content >3 times the serum amylase activity and with clinical consequence), the incidence of postoperative PF is between 15 and 30 %. Most POPF resolve spontaneously but when refractory POPF occurs, it may lead to severe complications. POPF severity is graded as follows: grade B in case of change in medical management: infection without organ failure, specific medication (total parenteral nutrition, somatostatin analogs, antibiotics), persistent drainage > 3 weeks, angiographic procedure for bleeding, prolonged hospital stay; grade C in case of reoperation or PF-related organ failure or death. No specific prophylactic treatment of POPF is currently recommended by clinical guidelines. In clinical research, many prophylactic strategies have been attempted with partial efficacy. Endoscopic pancreatic sphincterotomy with plastic stent placement is effective in pre-and postoperative management of pancreatic fistula but with the need of a highly competent interventional endoscopist. Intrapapillary botulinum toxin injection is believed to induce relaxation of the pancreatic sphincter, leading to a " pharmacological " pancreatic sphincterotomy without any morbidity. A recent phase I/II prospective study has shown promising results in this indication, with no clinically relevant pancreatic fistula when botulinum toxin was injected. Based on this observation we hypothesize that intrapapillary botulinum toxin injection during an endoscopic procedure before surgery could be effective for the prevention of post-surgical pancreatic fistula


Description:

Surgery is required for the treatment of many pancreatic conditions, either malignant or benign. Mortality of pancreatic surgery can be up to 3% even in expert centers. Morbidity is high, postoperative pancreatic fistula (POPF) being the main postoperative complication. In its current definition (drain output of any measurable fluid >= postoperative day 3 with amylase content >3 times the serum amylase activity and with clinical consequence), the incidence of postoperative PF is between 15 and 30 %. Most POPF resolve spontaneously but when refractory POPF occurs, it may lead to severe complications. POPF severity is graded as follows: grade B in case of change in medical management: infection without organ failure, specific medication (total parenteral nutrition, somatostatin analogs, antibiotics), persistent drainage > 3 weeks, angiographic procedure for bleeding, prolonged hospital stay; grade C in case of reoperation or PF-related organ failure or death. No specific prophylactic treatment of POPF is currently recommended by clinical guidelines. In clinical research, many prophylactic strategies have been attempted with partial efficacy. Endoscopic pancreatic sphincterotomy with plastic stent placement is effective in pre-and postoperative management of pancreatic fistula but with the need of a highly competent interventional endoscopist. Intrapapillary botulinum toxin injection is believed to induce relaxation of the pancreatic sphincter, leading to a " pharmacological " pancreatic sphincterotomy without any morbidity. A recent phase I/II prospective study has shown promising results in this indication, with no clinically relevant pancreatic fistula when botulinum toxin was injected. Based on this observation we hypothesize that intrapapillary botulinum toxin injection during an endoscopic procedure before surgery could be effective for the prevention of post-surgical pancreatic fistula This study will be a prospective, multicentric, phase III, superiority, controlled, randomized (1:1), open-label, clinical trial with two parallel arms (intrapapillary botulinum toxin versus standard care), using a PROBE (Prospective Randomized Open Blinded End-point) methodology. Patients with scheduled distal pancreatectomy for any indication Sources of funding for the trial : French Ministry supports this study by PHRC-N 2017. The botulinum toxin provides by MERZ France (producer of Xeomin)


Recruitment information / eligibility

Status Recruiting
Enrollment 460
Est. completion date March 1, 2027
Est. primary completion date December 31, 2026
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Patients with scheduled distal pancreatectomy for any indication: open or laparoscopic distal pancreatectomy with or without splenectomy - Age = 18years Exclusion Criteria: - History of myasthenia gravis or Eaton-Lambert syndrome - Inflammatory myositis <2 years or preexisting motor neuron disease or neuropathies - ASA score > III - Pregnancy or lactation - Altered anatomy of the duodenum and/or the major papilla (prior surgery, prior endoscopic sphincterotomy) - Scheduled pancreaticoduodenectomy (Whipple procedure) - Scheduled total pancreatectomy - Scheduled central pancreatectomy - Scheduled pancreatic enucleation - Calcified chronic pancreatitis (suspected on preoperative cross-sectional imaging) - Pancreas divisum (suspected on preoperative cross-sectional imaging) - Toxin botulinum contraindications (hypersensitivity to albumin or to saccharose, infection or inflammation at the injection site concerned, generalized muscle weakness) - Preoperative administration of somatostatin analogs: for long-acting somatostatin analogs, a 1-month washout period is necessary; for short-acting somatostatin analogs, a 24-hours washout period is necessary - Any kind of surgical method to reinforce the pancreatic stump: - Use of a bioabsorbable patch - Use of fibrin glue - Use of a ligament patch - Tutorship, trusteeship - Concurrent participation in other experimental trials - Not Affiliation to the French social security - Not Ability to give their consent and not written informed consent - Distal pancreatectomy extended to neighbouring organs (except spleen and gallbladder) or to the vessels (celiac axis, portal vein) Secondary exclusion criteria: patients who did not have the planned surgery in less than 4 weeks after the botulinum toxin injection.

Study Design


Intervention

Drug:
botulinum toxin injection
injection of Botulinum toxin A 100 UI, single dose administration, in the major papilla, in the Oddi sphincter, during upper gastrointestinal endoscopy.

Locations

Country Name City State
France PRAT Clichy

Sponsors (1)

Lead Sponsor Collaborator
Assistance Publique - Hôpitaux de Paris

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary number of postoperative pancreatic fistula Clinically relevant POPF (grade B and C) in the 3 months after Distal Pancreatectomy 3 months
Secondary number of postoperative pancreatic fistulas grade B Grade of postoperative pancreatic fistulas B based on the ISGPF 2016 update 3 months
Secondary number of postoperative pancreatic fistulas grade C Grade of postoperative pancreatic fistulas C based on the ISGPF 2016 update 3 months
Secondary Quantity of Biochemical leak after surgery Biochemical leak after surgery 3 months
Secondary number of Postoperative complications Postoperative complications :
intra-abdominal fluid collection
delayed gastric emptying
hemorrhage
pancreatitis
wound infection
other infectious complication
3 months
Secondary CLAVIEN-DINDO classification for post-surgical morbidity CLAVIEN-DINDO classification for post-surgical morbidity 3 months
Secondary Number of hospital days Health economics endpoints : duration of hospital stay 3 months
Secondary Number of hospital readmissions Health economics endpoints : hospital readmissions 3 months
Secondary Number of transfer to intensive care unit and the duration of these stays Health economics endpoints : transfer to intensive care unit and the duration of these stays 3 months
Secondary Number of fistularelated postoperative invasive procedures Health economics endpoints : fistularelated postoperative invasive procedures 3 months
Secondary overall costs of hospitalization Health economics endpoints : overall costs 3 months
Secondary Quality of life EQ-5D-5L questionnaire The descriptive system comprises five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems. The patient is asked to indicate his/her health state by ticking the box next to the most appropriate statement in each of the five dimensions. This decision results in a 1-digit number that expresses the level selected for that dimension. The digits for the five dimensions can be combined into a 5-digit number that describes the patient's health state : LEVEL 1: indicating no problem LEVEL 2: indicating slight problems LEVEL 3: indicating moderate problems LEVEL 4: indicating severe problems LEVEL 5: indicating unable to/extreme problems 3 months
Secondary Number of sides effects (complications) related to the endoscopic botulinum toxin injection number of sides effects (complications) related to the endoscopic botulinum toxin injection 3 months
See also
  Status Clinical Trial Phase
Recruiting NCT06289803 - The Application of Probe Confocal Laser Endomicroscopy in Pancreatic Tumor Surgery N/A
Completed NCT01988519 - Randomized Controlled Trial Comparing Closed-suction Drain Versus Passive Gravity Drain Following Pancreatic Resection N/A
Completed NCT03314337 - Pancreatic Stent for Distal Pancreatectomy N/A
Completed NCT00931554 - Randomized Trial of Early Versus Standard Drainage Removal After Pancreatic Resections N/A
Recruiting NCT03880773 - Comparison Between Two Methods of Pancreatic Transection in Distal Pancreatectomy N/A
Completed NCT05789459 - Comparison of Outcomes With Stapler Versus Hand-Sewn Closure After Minimally Invasive Distal Pancreatectomy
Completed NCT06084975 - Comparison of Outcomes Between Warshaw and Kimura Techniques for Spleen-preserving Minimally Invasive Distal Pancreatectomy
Completed NCT03481803 - A Phase IIa Study With Escalating Dose of MS1819-SD Phase 2
Not yet recruiting NCT06141044 - Prophylactic Abdominal Drainage vs no Drainage After Distal Pancreatectomy N/A
Completed NCT05423288 - Textbook Outcome in Distal Pancreatectomy
Recruiting NCT06123013 - Music Therapy in Patients Undergoing Pancreatic Surgery (MUSIC PUPS) N/A
Terminated NCT01051856 - TissueLink Versus SEAMGUARD After Distal Pancreatectomy Phase 4
Withdrawn NCT00671463 - Pancreatic Stent to Prevent Leak After Distal Pancreatectomy N/A